Dr. Michael Deininger -Chronic Myeloid Leukemia - CML

Chief, Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine
University of Utah
Huntsman Cancer Institute


''Dr. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly targeted therapies for hematologic malignancies. The major focus of his lab is the molecular basis of resistance to tyrosine kinase inhibitors such as imatinib, a drug used to treat chronic myeloid leukemia and some other types of cancer. They are currently developing biomarker strategies to predict both response and resistance to tyrosine kinase inhibitor therapy.''
Extract of Huntsman Cancer Institute

VIDEOS

Updates in CML: 2023 Best of Hematology
April 21, 2023, Total Health | Oncology

The Transformation of CML Treatment and Care
September 15, 2017, Patient Power

Debate: Is It Time for Discontinuing TKI Therapy in CML Patients Outside of Clinical Trials?
March 25, 2016, Oncology.TV

Video Viewpoint on Community Oncology Clinical Debates: CML (Part1)            
July 9, 2012, IMERonline                                                                           

Video Viewpoint on Community Oncology Clinical Debates: CML (Part2)            
July 9, 2012, IMERonline

A Video Viewpoint: Expert Discussions on CML Clinical Debates                          
June 20, 2012, IMERonline

                 
​                   See also CML Experts in USA